With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications